Insmed Inc (INSM)vsNeurogene Inc (NGNE)
INSM
Insmed Inc
$148.31
+6.59%
HEALTHCARE · Cap: $29.99B
NGNE
Neurogene Inc
$22.03
+5.41%
HEALTHCARE · Cap: $299.88M
Smart Verdict
WallStSmart Research — data-driven comparison
NGNE leads profitability with a 0.0% profit margin vs -2.1%. INSM earns a higher WallStSmart Score of 39/100 (F).
INSM
Hold39
out of 100
Grade: F
NGNE
Avoid29
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Reasonable price relative to book value
Areas to Watch
1.5% revenue growth
0.0% earnings growth
Trading at 43.0x book value
ROE of -2.5% — below average capital efficiency
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : INSM
PEG of 1.09 suggests the stock is reasonably priced for its growth.
Bull Case : NGNE
The strongest argument for NGNE centers on Price/Book.
Bear Case : INSM
The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.
Bear Case : NGNE
The primary concerns for NGNE are Revenue Growth, EPS Growth, Market Cap.
Key Dynamics to Monitor
INSM profiles as a turnaround stock while NGNE is a value play — different risk/reward profiles.
NGNE carries more volatility with a beta of 1.69 — expect wider price swings.
INSM is growing revenue faster at 1.5% — sustainability is the question.
NGNE generates stronger free cash flow (-20M), providing more financial flexibility.
Bottom Line
INSM scores higher overall (39/100 vs 29/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Insmed Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.
Neurogene Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Neurogene Inc. is a pioneering biotechnology firm specializing in the development of groundbreaking gene therapies aimed at addressing rare neurological disorders. With a focus on leveraging cutting-edge genetic medicine technologies, the company is committed to creating transformative treatments that meet significant unmet medical needs. Neurogene's robust pipeline of proprietary programs, coupled with its experienced leadership team, emphasizes its dedication to advancing the field of genetic therapies. As the company navigates its clinical development phases, it is well-positioned to enhance the quality of life for patients and families affected by genetic diseases.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?